2.50
Hdl Handle:
http://hdl.handle.net/10541/108100
Title:
The value of tumour markers in lung cancer.
Authors:
Gomm, S; Keevil, B; Thatcher, Nick; Hasleton, Philip S; Swindell, Ric
Abstract:
The pre-treatment serum levels of neuron-specific enolase (NSE), phosphohexose isomerase (PHI) and circulating immune complexes (CC) as tumour markers were compared to measurements of standard haematology and biochemical indices in 73 patients with lung cancer, as an aid to differentiation of tumour type, estimating disease extent, predicting response to therapy and prognosis. Elevated NSE greater than or equal to 12.5 ng ml-1, PHI greater than or equal to 55 mgl-1 levels were observed in 55% of cases for NSE, 90% for PHI and 49% for CC. NSE was significantly elevated in 61% (25/41) of patients with SCLC (P less than 0.005) compared to 41% (13/32) with NSCLC. CC levels were significantly raised in 72% (23/32) of patients with NSCLC (P less than 0.05) compared to 32% with SCLC. The levels of NSE and PHI were not related to tumour stage but CC was significantly raised in limited compared to extensive disease in SCLC (P less than 0.05). Serum albumin was significantly lower in NSCLC compared to SCLC, and median values of alkaline phosphatase, gamma-glutamyltranspeptidase and aminoaspartate transferase were significantly higher in patients with extensive disease. The pre-treatment serum values of NSE, PHI, and CC did not predict the response to therapy or prognosis in the 73 patients with lung cancer. The most important prognostic factor was the number of abnormal routine laboratory parameters (greater than 4) in this group of patients.
Affiliation:
Department of Thoracic Medicine, Wynthenshawe Hospital, Manchester, UK.
Citation:
The value of tumour markers in lung cancer. 1988, 58 (6):797-804 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Dec-1988
URI:
http://hdl.handle.net/10541/108100
PubMed ID:
2906254
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGomm, Sen
dc.contributor.authorKeevil, Ben
dc.contributor.authorThatcher, Nicken
dc.contributor.authorHasleton, Philip Sen
dc.contributor.authorSwindell, Ricen
dc.date.accessioned2010-07-21T15:14:21Z-
dc.date.available2010-07-21T15:14:21Z-
dc.date.issued1988-12-
dc.identifier.citationThe value of tumour markers in lung cancer. 1988, 58 (6):797-804 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid2906254-
dc.identifier.urihttp://hdl.handle.net/10541/108100-
dc.description.abstractThe pre-treatment serum levels of neuron-specific enolase (NSE), phosphohexose isomerase (PHI) and circulating immune complexes (CC) as tumour markers were compared to measurements of standard haematology and biochemical indices in 73 patients with lung cancer, as an aid to differentiation of tumour type, estimating disease extent, predicting response to therapy and prognosis. Elevated NSE greater than or equal to 12.5 ng ml-1, PHI greater than or equal to 55 mgl-1 levels were observed in 55% of cases for NSE, 90% for PHI and 49% for CC. NSE was significantly elevated in 61% (25/41) of patients with SCLC (P less than 0.005) compared to 41% (13/32) with NSCLC. CC levels were significantly raised in 72% (23/32) of patients with NSCLC (P less than 0.05) compared to 32% with SCLC. The levels of NSE and PHI were not related to tumour stage but CC was significantly raised in limited compared to extensive disease in SCLC (P less than 0.05). Serum albumin was significantly lower in NSCLC compared to SCLC, and median values of alkaline phosphatase, gamma-glutamyltranspeptidase and aminoaspartate transferase were significantly higher in patients with extensive disease. The pre-treatment serum values of NSE, PHI, and CC did not predict the response to therapy or prognosis in the 73 patients with lung cancer. The most important prognostic factor was the number of abnormal routine laboratory parameters (greater than 4) in this group of patients.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAlkaline Phosphatase-
dc.subject.meshAntigen-Antibody Complex-
dc.subject.meshAspartate Aminotransferases-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshFemale-
dc.subject.meshGlucose-6-Phosphate Isomerase-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPhosphopyruvate Hydratase-
dc.subject.meshPrognosis-
dc.subject.meshSerum Albumin-
dc.subject.meshTumor Markers, Biological-
dc.subject.meshgamma-Glutamyltransferase-
dc.titleThe value of tumour markers in lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Thoracic Medicine, Wynthenshawe Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.